NTLA:NASDAQ
Intellia
12,12 $US
arrow_upward
+0,50%(+0,060) 1J
12,12 $US
0,00% (0,00)
bedtimeAprès clôture
Fermé : 1 oct., 16:00:00 UTC−4 · USD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour NTLA...
Ouverture
11,98 $US
Élevé
12,66 $US
Faible
11,82 $US
Cap. boursière
1,70 Md
Vol. moyen
3,98 M
Volume
5,25 M
+ haut sur 1 an
28,24 $US
+ bas sur 1 an
7,95 $US
BPA
-3,36 $US
Bêta
1,82
Actions en circulation
140,13 M
Nombre d'employés
377
Ouverture
11,98 $US
Élevé
12,66 $US
Faible
11,82 $US
Cap. boursière
1,70 Md
Vol. moyen
3,98 M
Volume
5,25 M
+ haut sur 1 an
28,24 $US
+ bas sur 1 an
7,95 $US
BPA
-3,36 $US
Bêta
1,82
Actions en circulation
140,13 M
Nombre d'employés
377
Articles
Sources : Web et partenaires du secteur de l'information
Simply Wall Street
·
il y a 9 heures
Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now?
Investing.com South Africa
·
il y a 17 heures
Cathie Wood’s ARK buys Intellia stock, sells Alphabet shares By Investing.com
Yahoo Finance
·
il y a 2 jours
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Profil
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
À propos de Intellia
PDGJohn Leonard
Employés377
Date de création2014
Siège socialCambridge, Massachusetts, États-Unis
Secteur-
Site Webintelliatx.com